Correlation of Portal and Peripheral Venous ctDNA in Pancreatic Adenocarcinoma
NCT06478056 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40
Last updated 2026-02-06
Summary
This study aims to evaluate the prognostic impact of the detection of circulating tumor DNA in peripheral venous blood, portal venous blood, collected intraoperatively, as well as its detection in peritoneal fluid.
Conditions
Interventions
- PROCEDURE
-
pancreatectomy
patients operated on for pancreatic adenocarcinoma in the digestive surgery department of Rouen University Hospital
Sponsors & Collaborators
-
University Hospital, Rouen
lead OTHER
Study Design
- Allocation
- NA
- Purpose
- OTHER
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-05-28
- Primary Completion
- 2025-10-22
- Completion
- 2025-10-22
Countries
- France
Study Locations
More Related Trials
-
ctDNA Assay in Patients With Resectable Pancreatic Cancer
NCT05052671 ·Status: RECRUITING
-
The Influence of Secretin Stimulated Pancreatic Secretion on ctDNA Expression in Patients With Pancreatic Ductal Adenocarcinoma: The Role of Biomarkers in Determining the Prognosis of Pancreatic Ductal Adenocarcinoma
NCT06807112 ·Status: NOT_YET_RECRUITING
-
PDAC Peripheral and Portal Vein Sampling
NCT04289961 ·Status: COMPLETED ·Phase: NA
-
Implementing ctDNA and Circular DNA in Patients With Localized Pancreatic Cancer
NCT05788744 ·Status: RECRUITING ·Phase: NA
-
Multicenter Study of Circulating Tumor DNA in Patients With Pancreatic Cancer Using a Personalized Panel
NCT06043921 ·Status: RECRUITING
-
Pancreatic Adenocarcinoma Gene Environment Risk Study
NCT00912717 ·Status: RECRUITING
-
Optical and Biochemical Biomarkers in Early Pancreatic Cancer
NCT03404661 ·Status: COMPLETED
-
Evaluating the Response to Neoadjuvant Chemotherapy With Circulating Tumor DNA in Pancreatic Cancer
NCT04616131 ·Status: UNKNOWN
-
Circulating Tumor Cells in Operative Blood
NCT02150746 ·Status: COMPLETED
-
Application of ctDNA in Evaluation of Neoadjuvant Chemotherapy Efficacy and Exploration of Chemoresistance Mechanisms in Pancreatic Cancer
NCT05848154 ·Status: NOT_YET_RECRUITING
-
CtDNA-guided Maintenance Therapy in Pancreatic Cancer
NCT07054879 ·Status: RECRUITING
-
Defining a Vascular Phenotype of Pancreatic Ductal Adenocarcinoma With CT Perfusion Using Quantitative Radiomics
NCT05669287 ·Status: UNKNOWN ·Phase: NA
-
A Preoperative Model to Predict the Lymphovascular Invasion in Pancreatic Ductal Adenocarcinoma
NCT05997147 ·Status: UNKNOWN
-
Bonds Between Circulating Tumoral ADN (ctDNA) and the Development of Peritoneal Carcinomatosis for Patients Under PIPAC
NCT04766502 ·Status: COMPLETED ·Phase: NA
-
Prognostic Role of Circulating Tumor DNA in Resectable Pancreatic Cancer
NCT04246203 ·Status: ACTIVE_NOT_RECRUITING
-
Early Recurrence After Surgery for Pancreatic Cancer
NCT07241676 ·Status: ENROLLING_BY_INVITATION
-
Identification of Biomarkers Associated With the Presence of Malignant Pancreatic Lesions Compared to Benign Lesions.
NCT06397846 ·Status: RECRUITING ·Phase: NA
-
PANCREATIC CANCER: DYNAMIC ASSESSMENT AT ALL STAGES OF TREATMENT
NCT05802485 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Gemcitabine Hydrochloride in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery
NCT01416662 ·Status: COMPLETED ·Phase: PHASE2
-
Diagnostic Accuracy of Circulating Tumor Cells (CTCs) and Onco-exosome Quantification in the Diagnosis of Pancreatic Cancer - PANC-CTC
NCT03032913 ·Status: COMPLETED
-
Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals
NCT06122896 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Prospective Cohort of Patients Treated Using Neoadjuvant Modified FOLFIRINOX 6 Cycles for Potentially Resectable Pancreatic Duct Adenocarcinoma, Candidate for Participation in the PANACHE02 Clinical Trial
NCT07034703 ·Status: NOT_YET_RECRUITING
-
A Longitudinal, Observational Biomarker Study in Pancreatic Cancer Patients Receiving Chemotherapy
NCT04281511 ·Status: COMPLETED
-
CIrculating Tumor DNA for Monitoring Response to First Line Chemotherapy in Unresectable PANcreatic Cancer
NCT04560270 ·Status: COMPLETED ·Phase: NA
-
Panc CA Risk Model & Biomarker Testing In High-Risk Cohort
NCT05287347 ·Status: WITHDRAWN